Talk:Inflammatory breast cancer

this
this needs a merge with KEEPING the info about bug bites / embarassed teens. the word needs to get out, and it will do so much better on the larger and more visited BC page. moving this info there might just save a life.

Merging with other types of Breast Cancer:
Inflammatory breast cancer should have a separate section because one of the only things that it has in common with other types of breast cancer is that it usually involves the breasts. Inflammatory breast cancer normally presents with very different symptoms than other types of breast cancer in that it usually does not form a lump and is not detectable on a mammogram or ultrasound. Many IBC patients receive clear mammograms shortly before they are diagnosed with IBC. IBC is also much deadlier than the normal types of breast cancer. Statistics are indicating that breast cancer has a 97-98% survival rate, but IBC patients are lucky if 40% of them survive for even 5 years. Their 10-year survival rates are much lower. IBC is the most aggressive of the breast cancers and is much more likely to metastasize (spread). IBC should almost always be treated with chemotherapy first to decrease the size of the breast and increase the chances for clear margins, whereas most types of breast cancer receive surgery first. IBC almost always causes pain whereas other types of breast cancer rarely do in the initial stages. IBC is staged as either III or IV. It is never staged as I or II like most other breast cancers. IBC patients are almost never able to receive a lumpectomy - especially compared to many, if not most, other types of breast cancer. I could go on and on regarding the differences between IBC and other types of breast cancer. It is a disservice to the medical community, breast cancer patients, and the general public to not reinforce the differences and seriousness of Inflammatory breast cancer compared to more common types of breast cancer.


 * You will agree that IBC is a type of BC. That article happens to be in dire need of a serious cleanup, but I would recommend a merge. As a clinical entity, IBC is treated as breast cancer - surgically, with chemotherapy. I am I favour of reducing the content of this article to a clear concise paragraph in breast cancer. JFW | T@lk  03:43, 14 Sep 2004 (UTC)


 * I agree with JFW. Even though IBC is treated differently, this is an encyclopedia article not a support group.  Considering metastatic breast cancer doesn't have its own page (and that's a much bigger topic), this can be easily combined. Pete Bevin 10 Apr 2005


 * I am in favour of keeping a separate entry - imho IBC is a distinct lexical entity and that is reason enough for an own entry. It needs a cleanup, thats for sure. The part about teenagers needs fixing as IBC affects almost all age groups. --Richiez 20:38, 13 February 2007 (UTC)

A pathologic complete remission (pCR) predicts improved survival in breast cancer (BC)ASCO abstract describes a 63% rate of complete pathologic response in Her-2+ inflammatory breast cancer following paclitaxel/carboplatin and trastuzumab. ASCO 2006;abstract #10583 Authors: Mehta RS, Schubbert T, Kong K A pathological complete remission (pCR) predicts improved survival in breast cancer (BC). Treatment with AC followed by concurrent TCH improved pCR rates to 87.5% in Her2 positive 8-patient pilot study (SABCS 2004, abs #1110), confirmed by a subsequent phase II study. We hypothesized that response adjusted AC (2-4 cycles), TCH (3-4 cycles) sequence targets topoisomerase II alpha amplified and deleted clone, respectively (SABCS 2005, abs # 5056). We report here the combined analysis of the Her2 positive (fluorescence in situ hybridization + or immunohistochemistry 3+) subset of these studies. Material and Methods: Thirty-one patients with stage IIB-IV BC were accrued. Twenty-eight of 31 patients received AC in a dose dense manner with GM-CSF support. Patients received carboplatin calculated at AUC of 2 and paclitaxel at 80 mg/m2 for 3 weeks followed by 1 week of rest (1 cycle) for a maximum of 4 cycles. Concurrent trastuzumab 4 mg/kg loading dose, then 2 mg/kg/wk was administered for 12-16 weeks. Results: Twenty-nine of 31(94%, CI, 0.79-1) patients showed a clinical complete or partial response (cCR, or cPR). Nineteen of 27 patients (70%, CI, 0.50-0.86) achieved a pCR at surgery; two additional patients had <3 mm residual invasive cancer; and lymph node negativity rate was 73%. Of the 3 additional patients with cCR, 1died (underlying cirrhosis), 1 refused surgery, and 1 awaits surgery. A fourth patient with cPR awaits surgery. Ninety percent of the patients (28/31, CI, 0.74-0.98) are alive, and 77% (24/31, CI, 0.59-0. 90) are progression free at median follow up of 19 months (range 6-35 months). Median ejection fraction by echocardiogram was 60% (range 50-74); no patient had clinical cardiac dysfunction. One patient each on GM-CSF and peg-GCSF developed neutropenic fever. Conclusion: Short course of TCH following response adjusted 2-4 cycles of AC will have an improved therapeutic ratio with minimum cardiac toxicity and maximal response.See the table in the abstract for the inflammatory breast cancer subset.

Prevention
This section seems completely out of place here. There is absolutely zeor evidence that any of this would do anything to prevent IBC. Richiez (talk) 22:44, 19 August 2010 (UTC) Chemoprevention is a way to help reduce the chances of women getting breast cancer. Two common types of medicine used are tamoxifen and raloxifene.

Tamoxifen is FDA approved. It reduces the effects of estrogen, which influences breast tumor growth in women 35 and over. It is used in patients who have had breast cancer to prevent recurrence, as it is shown to improve the risk of recurrence. Trials have been done worldwide to see if tamoxifen would work with women who did not have cancer but had a high risk of getting it. Studies show that it lowered the women’s risk by one-third. It also showed that the women were still at low risk five years after they stopped taking the pill.

Side effects include menopausal symptoms, weight gain, life-threatening blood clots, cancer of the womb lining for post-menopausal women, bladder and urinary problems, vaginal discharge, vaginal dryness, nausea and menstrual irregularities, strokes, cataracts, and endometrial cancer or uterine cancer.

Some benefits of tamoxifen include lowering cholesterol for post-menopausal women and keeping bones healthy and strong. In pre-menopausal women, estrogen reduces risks of weak bones and heart disease.

Raloxifene is FDA approved. This pill is used to reduce breast cancer risk in post-menopausal women. It is also approved for helping to prevent bone weakening and osteoporosis. There was a study done that shows that raloxifene did not prevent the risk of non-invasive breast cancers as well as tamoxifen did.

Side effects include blood clots, uterine cancers, hot flashes, vaginal dryness, vaginal irritation, flu-like symptoms, leg cramps, swelling of hands or feet, and strokes.

Benefits include improved bone strength and reduced risk of osteoporosis.

Aromatase inhibitors are not FDA approved for prevention of breast cancer. These inhibitors reduce the amount of estrogen that the body produces, depriving cancer cells of getting their food to grow. These are commonly used after surgery to prevent recurrence. Aromatase inhibitors are only used for postmenopausal women.

Side effects include hot flashes, headache, joint and muscle pain, and vaginal dryness.

Risks include broken bones and osteoporosis.

Recent update..
I was struggling to find any news at all. seems encouraging as of survival rates but I was surprised how little new research turned up. Richiez (talk) 22:59, 24 January 2013 (UTC)

Many mentions of research findings on IBC; very few in line citations backing them up
Prior editors have added many interesting research findings to this article, yet have completely neglected to add citations to the studies which generated the findings. Any editors interested in this topic are most welcome to go to the literature, find citations, and, further, add any recent findings (with cites, of course) to update the article.--Quisqualis (talk) 00:29, 11 February 2020 (UTC)